Development Pipeline

Exponential Therapeutics is advancing a structured research program focused on evaluating whether controlled, reversible induction of hTERT can be translated into a viable therapeutic strategy. Our development pathway is designed to move from foundational proof-of-concept through progressively more rigorous validation and preclinical evaluation.

Rather than pursuing rapid expansion, our approach is intentionally phased—prioritizing clarity, control, and reproducibility at each stage. As a companion to this page, also see: From Hypothesis to Proof: How Do You Actually Test Controlled Telomerase Activation?

Phase 1: Proof of Concept

This initial phase is designed to directly test the core scientific hypothesis: whether hTERT expression can be induced in a controlled, measurable, and reversible manner using small molecules.

Key objectives include:

• Demonstrating reliable induction of hTERT expression
• Characterizing dose-response relationships
• Evaluating reversibility following removal of the inducing agent
• Assessing early cellular responses and markers of senescence
• Identifying initial safety signals in controlled systems (including cytotoxicity)
• Replication of results across multiple cell types

Experimental evaluation in this phase includes direct measurement of telomere dynamics, telomerase activity, and cellular outcomes using established assays. These include qPCR and Q-FISH for telomere length, TRAP assays for telomerase activity, and assessment of senescence and genomic stability markers such as β-galactosidase staining, p16/p21 expression, and γ-H2AX foci.

Studies are designed to evaluate dose-response relationships, reversibility following withdrawal, and longitudinal cellular behavior across multiple passages, providing a structured framework for identifying both beneficial effects and potential risk thresholds.

The goal of this phase is not broad application, but clarity—establishing whether controlled telomerase induction behaves in a predictable and testable manner.

Phase 2: Validation and Expansion

Following successful proof-of-concept, the program expands into broader validation across additional models and conditions. This phase focuses on strengthening confidence in both efficacy and control.

Key objectives include:

• Extended evaluation of telomere maintenance over time
• Further characterization of control parameters (dose, duration, distribution)
• Exploration of cellular response pathways (e.g. using RNA-seq)
• Identification of optimal therapeutic windows

This phase is designed to transition from initial signal detection to reproducible and scalable biological effects.

Phase 3: Preclinical Development

With sufficient validation, the program advances toward preclinical development. This phase focuses on translating controlled telomerase induction into a framework suitable for therapeutic development.

Key objectives include:

• Evaluation in relevant biological models
• Preliminary pharmacokinetic and pharmacodynamic profiling
• Safety and toxicity assessment
• Identification of potential disease applications
• Preparation for regulatory pathway considerations

This phase represents the transition from exploratory research into structured therapeutic development.

Our Approach to Development

Exponential Therapeutics is intentionally focused on capital-efficient, hypothesis-driven progress. Each phase is designed to answer specific, testable questions before advancing to the next stage.

By prioritizing control, reproducibility, and clear experimental outcomes, we aim to build a strong scientific foundation before scaling into larger development efforts.

Looking Ahead

Our long-term objective is to determine whether controlled, reversible telomerase induction can form the basis of a new class of therapeutics targeting cellular aging and age-related disease.

Progress in this field requires both scientific rigor and disciplined execution. Exponential Therapeutics is focused on advancing step by step—ensuring that each stage is supported by clear and reproducible evidence.

Partner With Us

Exponential Therapeutics is currently seeking strategic partners and aligned investors interested in advancing early-stage scientific research focused on cellular aging and telomerase control.

For inquiries, please contact us at

info@exponentialtherapeutics.com